Wall Street analyst estimates for NewAmsterdam Pharma Company N.V. (NAMS): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
Valuation Ratios
| Price / Book | 5.45 |
| EV / EBITDA | -14.54 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | $102.7M | $14.1M | $45.6M | $22.5M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 | $59000 |
| Gross Profit | 0 | 0 | $102.7M | $14.1M | $45.6M | $22.4M |
| Research & Development | $4.9M | $29.0M | $86.7M | $159.4M | $151.4M | $141.8M |
| Selling, General & Admin | $1.7M | $5.7M | $19.5M | $37.6M | $70.4M | $106.3M |
| Operating Expenses | $6.6M | $35.0M | $106.3M | $197.1M | $221.9M | $248.1M |
| Operating Income | -$6.6M | -$35.0M | -$3.6M | -$183.0M | -$176.3M | -$225.7M |
| EBITDA | -$6.6M | -$41.4M | -$22.3M | -$176.9M | -$241.5M | -$242.3M |
| Interest Expense | 0 | $411000 | $287000 | $6.8M | 0 | 0 |
| Pre-tax Income | -$7.0M | -$41.8M | -$22.6M | -$176.9M | -$241.6M | -$203.8M |
| Income Tax | 0 | 0 | 0 | $27000 | -$1000 | 0 |
| Net Income | -$7.0M | -$41.8M | -$22.6M | -$176.9M | -$241.6M | -$203.8M |
| EPS | $0.00 | $-3.34 | $-1.19 | $-2.15 | $-2.56 | $-1.75 |
| EPS (Diluted) | $0.00 | $-3.34 | $-1.19 | $-2.15 | $-2.56 | $-1.75 |
| Shares Outstanding (Diluted) | $17.8M | $17.8M | $19.0M | $82.2M | $94.4M | $114.4M |
Price
| Price | $21.18 |
| Market Cap | $2.5B |
| Exchange | NASDAQ |
| Country | NL |
Related companies: ACLX · AKRO · CGON · CRNX · IMVT · KYMR · LGND
Explore sector: Healthcare · Biotechnology
More sections of NAMS: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks